These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26342407)

  • 21. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
    Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
    Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
    Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
    Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H; Hara I; Kamidono S; Gleave ME
    Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
    Bozec A; Sudaka A; Etienne-Grimaldi MC; Brunstein MC; Fischel JL; Milano G
    Oral Oncol; 2011 Oct; 47(10):940-5. PubMed ID: 21862388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
    Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice].
    Wang N; Wang B; Wang YJ
    Ai Zheng; 2006 Sep; 25(9):1076-81. PubMed ID: 16965645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
    Black PC; Brown GA; Dinney CP; Kassouf W; Inamoto T; Arora A; Gallagher D; Munsell MF; Bar-Eli M; McConkey DJ; Adam L
    J Urol; 2011 Feb; 185(2):693-700. PubMed ID: 21168861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
    Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
    Ghosh S; Maity P
    Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells.
    Ho JN; Byun SS; Lee S; Oh JJ; Hong SK; Lee SE; Yeon JS
    J Urol; 2015 Mar; 193(3):1016-22. PubMed ID: 25229559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of heparin-polyethyleneimine nanogels delivering claudin-3-targeted short hairpin RNA combined with low-dose cisplatin on ovarian cancer.
    Liu L; Gou M; Yi T; Bai Y; Wei Y; Zhao X
    Oncol Rep; 2014 Apr; 31(4):1623-8. PubMed ID: 24482188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.